Rapamune (Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.)
Welcome to the PulseAid listing for the Rapamune drug offered from Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.. This Decreased Immunologic Activity [PE],mTOR Inhibitor Immunosuppressant [EPC],mTOR Inhibitors [MoA],Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. |
| NON-PROPRIETARY NAME: | SIROLIMUS |
| SUBSTANCE NAME: | SIROLIMUS |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Decreased Immunologic Activity [PE],mTOR Inhibitor Immunosuppressant [EPC],mTOR Inhibitors [MoA],Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, SUGAR COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2010-03-01 |
| END MARKETING DATE: | 0000-00-00 |
Rapamune HUMAN PRESCRIPTION DRUG Details:
| Item Description | Rapamune from Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. |
| LABELER NAME: | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 0.5(mg/1) |
| START MARKETING DATE: | 2010-03-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0008-1040_d3bb2f6c-e26b-4623-bd8b-300db4c5d713 |
| PRODUCT NDC: | 0008-1040 |
| APPLICATION NUMBER: | NDA021110 |
Other SIROLIMUS Pharmaceutical Manufacturers / Labelers:
